Brief: Pepgen Announces Positive Preclinical Data For Pgn-Edo53, Pgn-Edo45 And Pgn-Edo44, Three Novel Duchenne Muscular Dystrophy Candidates
14/11/2022 17:39
Nov 14 (Reuters) - PepGen Inc PEPG.O :
* PEPGEN ANNOUNCES POSITIVE PRECLINICAL DATA FOR PGN-EDO53,
PGN-EDO45 AND PGN-EDO44, THREE NOVEL DUCHENNE MUSCULAR DYSTROPHY
CANDIDATES
Source text for Eikon: ID:nGNXbL7dpT
Further company coverage: PEPG.O
Recent news on PepGen
See all newsDyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
PepGen Inc. reports results for the quarter ended June 30 - Earnings Summary
PepGen Q2 net loss narrows as expenses fall
Brief: PepGen Q2 EPS USD -0.26
PepGen Inc expected to post a loss of 29 cents a share - Earnings Preview